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LOW AND HIGH AFF IN ITY  CELLULAR 
RECEPTORS FOR INTERLEUKIN  2 
Implications for the Level of  Tac Antigen 
BY RICHARD J. ROBB,* WARNER C. GREENE,* AND CYNTHIA M. RUSK* 
From the * Central Research and Development Department, E.L du Pont de Nemours & 
Company, Glenolden Laboratory, Glenolden, Pennsylvania 19036; and the *Metabolism 
Branch, National Cancer Institute, Bethesda, Maryland 20205 
Interleukin 2 (IL-2), 1 formerly called T cell growth factor, provides a necessary 
signal for the transition of activated T cells from the G1 to the S phase of the 
cell cycle (1, 2). The mechanism of action of the factor involves binding to a 
high-affinity receptor on the surface of responsive cells (3, 4). Based on a number 
of criteria, the murine monoclonal antibody anti-Tac, originally prepared by 
Uchiyama nd co-workers (5), recognizes the human IL-2 receptor. The antibody 
was capable of blocking high-affinity IL-2 binding to activated cells (6, 7) and all 
of the T cell responses attributed to interaction of such cells with IL-2 (8). 
Furthermore, a covalent complex of IL-2 and Tac protein was isolated from IL- 
2-treated cells that had been subjected to chemical cross-linking (9). Finally, 
affinity supports coupled with the antibody and with IL-2 bound the same 55,000 
mol wt glycoprotein from a mixture of detergent-solubilized cellular molecules 
(7). The antibody-coupled support was capable of removing all cellular proteins 
reactive with the IL-2-coupled support, and the IL-2-coupled support was 
capable of removing all antibody-reactive molecules. Thus, the number of IL-2 
receptors appeared equal to the number of Tac proteins. In contrast o the latter 
finding, quantitative binding assays with radiolabeled IL-2 and anti-Tac indicated 
that activated T cells had 10-20 times more binding sites for the antibody than 
high-affinity sites for IL-2(10). Resolution of this dilemma is essential if the anti- 
Tac reagent is to be used to monitor expression of the IL-2 receptor in the 
absence of direct binding data. 
As earlier suggested (7), one potential explanation for the quantitative differ- 
ence between the two binding assays is that a large portion of the Tac proteins 
possess a low affinity for IL-2. Such molecules would bind to IL-2-coupled 
supports but would not have appeared in the original radiolabeled IL-2 binding 
assays (3), which were conducted at very low IL-2 concentrations. In this paper, 
we describe a binding phenomenon for IL-2 on activated T cells and certain B 
cells that has an association constant >5,000 times lower than that originally 
Abbreviations u ed in this paper: BSA, bovine serum albumin; CTLL, cytolytic T lymphocyte 
line; DME, Dulbecco's modified Eagles medium; FBS, fetal bovine serum; HCL, hairy cell eukemia; 
HTLV, human T cell leukemia virus; IgG, immunoglobulin G; IL-2, interleukin 2;Kd, dissociation 
constant; leu, leucine; lys, lysine; PBL, peripheral b ood mononuclear lymphocyte; PHA, phytohe- 
magglutinin; PMA, phorbol-12-myristate-13-acetate; SDS-PAGE, sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis; TdR, thymidine. 
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described (3). Moreover, the number of such binding sites was many times the 
number of high-affinity sites. As with the high-affinity interaction, the low- 
affinity binding of  radiolabeled IL-2 was blocked by addition of  excess unlabeled 
factor and substantially blocked by the addition of  the anti-Tac antibody. Con- 
sidering the accuracy of  the methodology, the levels of  total binding sites 
measured using radiolabeled IL-2 and anti-Tac were quite similar, thus support- 
ing the notion that the two assays detect coincident sets of  molecules. 
Mater ia ls  and  Methods  
Cell Cultures. The three murine, IL-2-dependent cytotoxic T cell lines (CTLL-2, 
subclone 15H [ 11 ] and CTL, a gift from Dr. T. Malek, National Institutes of Health) and 
helper T cell lines (HT-2, a gift from Dr. T. Malek) were maintained in Iscove's modified 
Dulbecco's modified Eagle medium (Iscove's DME; Grand Island Biological Co., Grand 
Island, NY) supplemented with 15% heat-inactivated fetal bovine serum (FBS, M.A. 
Bioproducts, WalkersviUe, MD), 100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM t.- 
glutamine, 2.5 × 10 -5 M 2-mercaptoethanol, and 1.0 U/ml purified JURKAT-derived 
IL-2. All human and primate cell lines were maintained in RPMI 1640 medium (Grand 
Island Biological) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 
#g/rot streptomycin, and 2 mM L-glutamine. All cells were cultured in a humidified 
atmosphere of 5% CO2 in air at 37°C. The 1C9 cell line was obtained by transformation 
of Tac-positive, normal human B cells with Epstein-Barr virus and was a generous gift 
from Dr. T. Waldmann, National Institutes of Health. A sample of hairy cell leukemia 
(HCL) was a kind gift from Dr. S. Korsmeyer. T lymphocytes were first removed from 
this sample by sheep erythrocyte rosetting before receptor binding analysis. HSB~ cells (1 
x 106 cells/ml) were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate (PMA;
Consolidated Midlands Corp., Brewster, NY) for 20 h before receptor analysis. 
Human phytohemagglutinin(PHA)-activated lymphoblasts were prepared by culturing 
peripheral blood mononuclear cells isolated on Ficoll-Hypaque with 1.5 ~g/ml PHA (HA- 
16; Wellcome Reagents, England) in supplemented RPMI 1640 medium for 72 h. The 
proportion of blast cells was enriched to >95% by discontinuous Percoll (Pharmacia, Inc., 
Uppsala, Sweden) gradient centrifugation (12). For short-term culture of PHA-lympho- 
blasts, the 72-h blast cells were washed and resuspended at 1 × 105 cells/ml in supple- 
mented RPMI 1640 with 1 U/ml IL-2. Every 48 h, the cells were pelleted and resuspended 
in fresh medium containing IL-2. At 9 d after the original lectin stimulation, the cells 
were restimulated with 1.0 #g/ml PHA in the presence of IL-2. Receptor expression was 
measured after 16 h. 
Interleukin 2. Biosynthetically radiolabeled and unlabeled IL-2 were prepared from 
the cell supernatant ofa high-producing subclone of the JURKAT cell line (16.8.9.15.32) 
after induction of the cells with PHA and PMA (13). The cells were suspended at 4 x 
106/ml in serum-free DME for the preparation of unlabeled IL-2 and in leucine, lysine- 
free DME (Grand Island Biological Co.), to which was added 40 #M unlabeled leucine 
and 65 #M unlabeled lysine, for the radiolabeled preparations. To the latter cultures were 
added 0.1-0.5 mCi/ml [aH]leucine (50 Ci/mmol; ICN, Irvine, CA) and 0.1-0.5 mCi/ml 
[3H]lysine (45 Ci/mmol; ICN). IL-2 secretion was induced by inclusion of 1.5 #g/ml PHA 
and 50 ng/ml PMA. The cell supernatant was harvested after 16 h at 37°C. Bovine serum 
albumin (BSA; Sigma Chemical Co., St. Louis, MO) at 1 mg/ml was added to the 
radiolabeled preparations a a carrier. 
IL-2 was purified from theJURKAT cell supernatant using an immunoaffinity column 
coupled with a murine monoclonai ntibody (46C8-A2) specific for the N-acetyl galactos- 
amine derivative of human I L-2 (14, 15). This form of I L-2 represents -60 % of the factor 
released by stimulated J URKAT cells (16). Separate xperiments have demonstrated that 
the affinity of IL-2 for its cellular eceptor is not affected by the extent of glycosylation 
of the factor (3, 15). Bound IL-2 was recovered in >95% yield by elution of the affinity 
column with 1.5% HOAc. The recovered unlabeled factor was judged to be >99% pure 
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by two-dimensional gel electrophoresis (16), reverse-phase HPLC (unpublished observa- 
tion), and N-terminal sequence analysis (16). The material was free of PHA and PMA, 
based on the gel electrophoretic data and [sH]PMA (New England Nuclear, Boston, iMA ) 
tracer analysis (16). The radiolabeled IL-2 was eluted from the affinity column in 1.5% 
HOAc with 1 mg/ml BSA and equilibrated with RPMI 1640, 25 mM Hepes, pH 7.2 
(Grand Island Biological Co.) on a YM-5 membrane (Amicon Corp., Lexington, MA). 
The specific radioactivity of [SH]ieu,lys IL-2, in terms of dpm SH per picomole IL-2, was 
estimated by measuring the bioactivity of the preparation i the T cell proliferation assay 
(see next section) and converting this value to the weight of IL-2 using the previously 
determined specific activity of the factor (3 I0,000 units of bioactivity per milligram of 
IL-2 protein; reference 16) and its molecular weight (15,500 pg/pmol). 
lnterleukin 2Bioassay. IL-2 bioactivity was determined by the concentration-dependent 
stimulation of proliferation, as indicated by [3H]thymidine (TdR) incorporation, of a 
cloned, IL-2-dependent murine T cell line (CTLL-2, subclone 15H) (17). Serial twofold 
dilutions of the samples and a standard IL-2 preparation were incubated with 4,000 
CTLL cells (200 #1 total volume) for a period of 16-18 h. At that time, the cultures were 
pulsed with 50 ~l of [SH]TdR, 10 ~Ci/ml (New England Nuclear). After 4 h, the cultures 
were harvested on glass fiber paper using a Titertek Cell Harvester (Flow Laboratories, 
Rockville, MD). The dilutions yielding half-maximal [SH]TdR incorporation were deter- 
mined by probit analysis (17) and the dilution of the sample was divided by that of the 
standard to yield the IL-2 concentration i units per milliliter. The standard IL-2 
preparation was arbitrarily assigned a value of 1 U/ml and induced 50% of the maximum 
[SH]TdR incorporation ata final dilution of 1:20 to 1:40 (the final dilution after addition 
of 100 ~1 of the CTLL suspension) (13). As used here, 1 U of bioactivity was equivalent 
to ~41.5 IL-2 Reference Reagent "units" as defined by the Biological Response Modifiers 
Program of the National Cancer Institute. 
Anti-Tac Monoclonal Antibody. The anti-Tac antibody (5) was purified from the ascites 
fluid of hybridoma-inoculated BALB/c mice using protein A-Sepharose (Sigma). The 
antibody was radiolabeled by reductive methylation with formaldehyde and sodium 
[SH]borohydride (New England Nuclear) (9). The specific radioactivity was calculated 
using an average of the protein content as determined by the Lowry assay (18) and 
quantitative amino acid compositional nalysis. 
Radiolabeted IL-2 and Anti-Tac Binding Assays. Before determining the level of binding, 
all cell types were incubated twice for 1 h at 37°C in 50 ml RPMI 1640 with extensive 
washing between and after the incubations inorder to remove ndogenous IL-2. Previous 
studies (3, 19) have indicated that receptor-bound IL-2 will either dissociate or be 
internalized during this time period. In some cases, the washed cells were also incubated 
for 20 s in 10 mM sodium citrate, 0.14 M NaCI, pH 4.0 followed by centrifugation at
9,000 g for 15 s in a Microfuge 12 (Beckman Instruments, Palo Alto, CA), a procedure 
shown to remove intact cell surface-bound IL-2 (19). After washing, the cells were 
resuspended in RPMI 1640, 25 mM Hepes, pH 7.3, containing 10 mg/ml BSA (RPMI- 
BSA). Identical binding results were obtained using RPMI 1640 with 10% fetal calf serum 
in place of the BSA. 
To determine the level of binding, serial dilutions of [SH]leu,lys IL-2 and [!H]anti-Tac 
IgG were incubated at 37°C with 0.3-2 x 10 ~ cells in a total volume of I00 tA RPMI- 
BSA using 1.5-ml Eppendorf micro test tubes (Brinkman Instruments, Westbury, NY). 
For the anti-Tac binding assay, a control murine myeioma IgG2a antibody, designated 
UPC-10 (Litton Bionedcs Inc., Kensington, MD), was included at 200 ~tg/ml to minimize 
potential interactions of the [SH]anti-Tac with Fc receptors. The tubes were mechanically 
rotated about their longest axis (horizontal position) at 20 rpm in a 37°C water bath for 
20-30 min. In separate xperiments (unpublished observations), it was determined that 
this period of incubation was sufficient to allow maximum high (20 rain) and low-affinity 
(30 min) binding to occur. After incubation with the radiolabeled probe, the cells were 
washed two to four times, depending upon the amount of radiolabel added, with 1 ml ice- 
cold RPMI-BSA. The supernatant from the first wash was counted by liquid scintillation 
to determine the level of unbound IL-2 or anti-Tac antibody. The cells were resuspended 
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in 100 #! RPMI-BSA and centrifuged (9,000 g for 90 s) through a 200 #l layer of a 
mixture of 84% silicone oil (550 fluid; Contour Chemical Co., North Reading, MA) and 
16% paraffin oil (Fisher Scientific Co., Philadelphia, PA) to remove the small amount of 
residual unbound radioactivity. The tips of the tubes (400-#1 polyethylene; Bio-Rad 
Laboratories, Richmond, CA) containing the cell pellet were cut off and placed in 20-ml 
glass scintillation vials. The cells were expelled from the tips using 200 #1 phosphate- 
buffered saline (PBS) and solubilized by the addition of 200 #1 1% SDS, followed by 10 
ml Liquiscint (National Diagnostics, Somerville, N J). The radioactivity was counted by 
liquid scintillation on a Tri-Carb 4640 (Packard Instrument Co., Downers Grove, IL). 
The results were converted to dpm before applying graphical analysis. The average 
counting efficiency for the bound fraction was 39% and, for the unbound fraction, 32%. 
Results 
Purity of Radiolabeled Probes. The radiolabeled IL-2 and anti-Tac reagents 
were purified by affinity chromatography on anti-IL-2 monoclonal antibody and 
protein A-coupled columns, respectively. The [3H]IL-2 was prepared at several 
different levels of specific radioactivity in order to measure binding over a wide 
range of concentrations. SDS-polyacrylamide g l electrophoretic (SDS-PAGE) 
analysis of  the various radiolabeled probes indicated that each of the IL-2 
preparations consisted of a single labeled component of 15,500 tool wt and that 
the [3H]anti-Tac preparation :contained only the 50,000 and 25,000 mol wt 
bands expected of heavy and light IgG chains (Fig. 1). 
Extension of the [~H]IL-2 Binding Assay to High IL-2 Concentrations. The 
radiolabeled IL-2 binding assays originally described by Robb et al. (3) used 
IL-2 concentrations between 1 and 200 pM. At these IL-2 levels, the authors 
a b c d 
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FIGURE 1. SDS-PAGE analysis (12% acrylamide, samples treated with 2-mercaptoethanol, 
$ 5 reference 16) of three preparations of [ H]IL-2 with specific radioactivities of 3.82 × 10 dpm/ 
pmol (lane a), 2.42 × 105 dpm/pmol ( ane b), and 3.09 × 104 dpm/pmol ( ane c) and of [3HI 
anti-Tac antibody (8.33 × 104 dpm/pmol, ane d). About 20,000 dpm of each of the IL-2 
radiolabeled probes and 10,000 dpm of the anti-Tac probe were applied to the gel. The 
radioactivity was visualized by fluorography (36). 
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demonstrated a saturable binding phenomenon with a dissociation constant (Kd) 
of 5-6 pM for activated human T cells and 20 pM for activated murine T cells. 
The number of binding sites detected on the human cells, however, was far 
below that estimated using the anti-Tac monoclonal ntibody (6, 8, 10). A similar 
discrepancy was suspected for the murine T cells based on the intensity of 
fluorescence staining with a rat monoclonal ntibody (20) specific for the murine 
IL-2 receptor (unpublished observation)• Since it was possible that IL-2 might 
also interact with a distinct set of sites with a markedly lower affinity (7), the 
binding curve analysis was extended up to IL-2 concentrations 1,000-fold higher 
than originally used. The results of such a binding experiment, as shown in Fig. 
2, confirmed that high-affinity saturable binding occurred at IL-2 concentrations 
<1 nM. At IL-2 concentrations above this level, however, additional factor 
binding was detected. In this experiment, he Kd of the binding at high IL-2 
concentrations for the human T cell leukemia/lymphoma (HTLVI)-infected line, 
HUT 102B2, for human PHA-activated lymphoblasts, and for the murine, IL- 
2-dependent CTLL-2 line was estimated to be 15-30 nM, or ~5,000 times 
higher than that of the saturable binding at picomolar IL-2 levels. Furthermore, 
the number of such low-affinity binding sites was at least 5-10 times the number 
of high-affinity sites. Addition of 10 #M unlabeled IL-2 reduced the binding of 
[3H]IL-2 by 90% or more for each of the concentrations tested (Fig. 2). Thus, 
the low-affinity binding consisted predominately of a saturable component. 
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FIGURE 2. Typical curve for the binding of [~H]leu,lys IL-2 (2.42 × 105 dpm/pmol) to HUT 
102B2 cells, PHA-activated (72 h) human lymphoblasts, and murine CTLL-2, subclone 15H 
cells over a 100,000-fold range of IL-2 concentration. Nonsaturable binding on the HUT 
102B2 cells was estimated by including 10 #M unlabeled IL-2. 
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To further evaluate the proportion of saturable binding, serial dilutions of 
unlabeled IL-2 were added to [3H]leu,lys IL-2 at three different concentrations 
of the radiolabeled probe. The concentrations of radiolabeled IL-2 were chosen 
to examine high-affinity binding, low-affinity binding, and binding intermediate 
between these two extremes. As shown in Fig. 3, using HUT 102B2 and murine 
CTLL-2 cells, addition of increasing amounts of unlabeled IL-2 resulted in up 
to 99% inhibition of the binding of [3H]leu,lys IL-2 at a low concentration of the 
probe. Similarly, unlabeled IL-2 competed for up to 95 and 87% of the binding 
at intermediate and high levels of labeled factor. Since nonspecific binding 
increases linearly with the concentration of labeled probe, it was not unexpected 
that the level of nonsaturable binding remaining after cold competition repre- 
sented a larger fraction of the total binding for the low-affinity phenomenon 
than it did for the binding at picomolar concentrations of radiolabeled IL-2. The 
results demonstrate, however, that the low-affinity binding predominantly rep- 
resents pecific interaction of the factor with a cellular component(s). 
Relationship of lL-2 Binding to the Tac Antigen. Previous tudies (6, 7) indicated 
that the anti-Tac antibody could completely inhibit the binding of radiolabeled 
IL-2 at picomolar concentrations of the growth factor. To evaluate the affect of 
the antibody on low-affinity IL-2 binding, serial dilutions of anti-Tac were 
combined with different concentrations of the radiolabeled IL-2 probe. Anti- 
Tac inhibited >95% of the [3H]ieu,lys IL-2 binding to HUT 102B2 cells at the 
lowest concentration of IL-2 (high-affinity binding). At progressively higher IL- 
2 levels, a decreasing proportion of the binding was blocked (Fig. 4). Neverthe- 
less, at the highest IL-2 concentration, at which >90% of the binding should 
,oo  o.... __.220_; 
"~\  \~  ~ 1.9 x 10-TM 
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FIGURE 3. Competitive inhibition of the binding of [3H]leu,lys 1L-2 (3 different concentra- 
tions) by unlabeled IL-2 using HUT 102B2 and murine CTLL-2, subctone 15H cells. [SH l- 
leu,lys IL-2 at the concentrations i dicated inthe figure was combined with serial dilutions of 
unlabeled IL-2, followed by addition of the cells. The concentrations of radiolabeled IL-2 
were chosen to give saturation of the high-affinity binding sites (1.9 × 10 -~° M total concen- 
tration), half-saturation of the low-affinity binding sites (1.6 × 10 -8 M total concentration) a d 
saturation ofthe low-affinity binding sites (1.9 × 10 -7 M total concentration). 
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FIGURE 4. Inhibition of the specific binding of [SH]leu,lys 1L-2 (3 different concentrations) 
by unlabeled anti-Tac antibody using HUT 102B2 cells. [3H]leu,lys IL-2 at the concentrations 
indicated in the figure was combined with serial dilutions of anti-Tac antibody, followed by 
addition of the cells. Control murine IgG had no effect on the level of bound [SH]IL-2 even 
when present at 10 -5 M. The number of molecules of [3H]IL-2 bound per cell for each of the 
IL-2 concentrations was 4,720 (2.5 x 10 -~° M), 17,010 (1.6 X 10 -a M), and 64,400 (2.2 x 
10 -7 M). The results were first corrected for the levels of nonsaturable binding determined in
Fig. 3. 
have been of the low-affinity type, the antibody still inhibited 80-90% of the 
specific IL-2 binding. Thus, at least the majority of the low-affinity interaction 
of IL-2 with the HUT 102B2 cells appeared to involve the Tac protein. At the 
lowest concentration of [3H]IL-2, where the binding was entirely of the high- 
affinity type, a 55-fold molar excess of antibody over growth factor was required 
to reduce the receptor-association by half. In contrast, at the highest concentra- 
tion of [SH]IL-2, where most of the binding was low-affinity, the molar ratio of 
antibody to IL-2 at 50% inhibition was 1:130. Thus, anti-Tac was far more 
efficient in blocking the low-affinity phenomenon. 
In a second approach to evaluating the relationship of IL-2 binding to the Tac 
protein, serial dilutions of unlabeled IL-2 were tested for their efficacy in 
blocking the cellular binding of [SH]anti-Tac. The concentration of antibody 
used was sufficient for saturation of the anti-Tac binding sites. Furthermore, the 
number of antibody-binding sites detected in the controls exceeded by many 
fold the number of high-affinity IL-2 binding sites (see Table I). The results 
demonstrated that IL-2 could totally block the binding of labeled antibody to 
either HUT 102B2 or 1C9 cells (Fig. 5). Thus, all the Tac proteins on these 
cells appeared capable of interacting with IL-2. At the concentration of antibody 
chosen, a 100-fold molar excess of IL-2 over anti-Tac was necessary to cause a 
50% reduction in antibody binding. Half-maximal inhibition of anti-Tac binding 
occurred at the same IL-2 concentration for both cell lines. Interestingly, ~8% 
of the anti-Tac binding on the HUT I02B2 cells was inhibited at very low IL-2 
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FIGURE 5. Inhibition of the binding of [SH]anti-Tac ntibody (1.8 x 10 -9 M total concentra- 
tion) by serial dilutions of unlabeled IL-2 using HUT 102B2 and 1C9 cells. The radiolabeled 
antibody and IL-2 were combined before addition of the cells. The level of radiolabeled 
antibody was chosen to give saturation ofthe anti-Tac binding sites. 
levels. This amount is very similar to the fraction of high-affinity IL-2 binding 
sites present on this cell line (Table I). 
Scatchard Analysis of High and Low Affinity IL-2 Binding and of Anti-Tac Bind- 
ing. To evaluate the interaction of IL-2 with a variety of cell types, binding 
assays .were separately performed at high and low ranges of IL-2 concentration. 
The results (Figs. 6-8, Table I) indicated that at IL-2 concentrations below 1 
nM, saturable binding occurred to a variety of cell types that were positive for 
the IL-2 receptor as defined by monoclonal antibodies (6, 20). In addition, as 
was evident at IL-2 concentrations above 1 nM, each of these cell types also 
displayed many-fold higher levels of low-affinity IL-2 binding sites. In contrast, 
unstimulated cells (PBL) and a number of Tac-negative T cell lines, such as Molt 
3 andJURKAT,  and B cell lines, such as Raji and Daudi, lacked the capacity for 
significant high and low affinity IL-2 binding (Table I). The level of IL-2 binding 
on the receptor-positive c lls was only slightly increased by elution of endogenous 
factor with a low pH buffer (19). Thus, following preparation of the cells for the 
assay, 90% or more of the high and low affinity binding sites remaining on the 
cell surface appeared unoccupied (data not shown). 
PHA-activated lymphoblasts cultured in IL-2-containing medium for 10 d lost 
most of their high and low affinity receptors (Table I). Restimulation of these 
cells with PHA resulted in a dramatic reexpression of IL-2 binding capacity in 
parallel with an increase in their level of the Tac antigen. The 1C9 B cell line 
displayed both high and low affinity IL-2 binding sites, but the levels of both 
were far below those seen on activated T cells and the HUT 102B2 line (Table 
I). PMA-stimulated HSB2 cells and a sample of B cells of hairy cell leukemia 
origin, although positive for anti-Tac binding, displayed few, if any, high-affinity 
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FZGtJ~E 6. (A) Typical curves for the binding of [SH]leu,lys IL-2 (3.82 x 105 dpm/pmol) at 
low IL-2 concentrations (i.e., high-affinity binding) to HUT 102B2, PHA-activated (72 h) 
human lymphoblasts, 1C9 and murine CTLL 2, subclone 15H cells. Nonsaturable binding 
was estimated by including 10 ttM unlabeled IL-2 in selected tubes. The residual radiolabel 
associated with the cells was subtracted from the total bound fraction found in the absence of 
unlabeled factor to give specific binding. (B) A Scatchard plot of the data in A. 
IL-2 b ind ing sites (Table I). A lmost  all the sites on  these cells were  o f  the low- 
affinity variety. The  ratios o f  total IL-2 b inding sites for the three mur ine  cell 
l ines (Table I) were  approx imate ly  the same as the ratios o f  mean f luorescence 
intensity determined  with rat monoc lona l  ant ibody 7D4 (20), which is specific 
for the mur ine  IL-2 receptor  (data not  shown).  The  demonst ra t ion  o f  high levels 
o f  low-aff inity IL-2 b inding on these cell l ines is consistent with the intensity o f  
their f luorescence staining. 
Scatchard analysis o f  the assay results at low IL-2 concentrat ions  (Fig. 6B)  
p roduced straight lines, indicat ing that the b inding for each cell type over  this 
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lymphoblasts. The results were corrected for nonsaturable binding by measuring the residual 
binding in the presence of 10 uM unlabeled IL-2. (B) A Scatchard plot of the data in A (solid 
lines). The contribution of high-affinity binding sites was subtracted from the values of total 
bound factor to reveal the approximate characteristics of the low-affinity binding phenomenon 
(dashed lines). 
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range of IL-2 levels was characterized by a single affinity. The enormous 
difference in the dissociation constants for the high and low affinity phenomena, 
which was emphasized by the binding curves depicted in Fig. 2, explains why the 
low-affinity binding has no detectable ffect on the association curves at these 
IL-2 concentrations. The apparent dissociation constant, averaged over several 
experiments, was -4  pM for the human PHA-lymphoblasts and HUT 102B2 
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cells (Table I). This value is in good agreement with that previously measured 
(3), particularly when corrections (16) are made in the specific radioactivity of 
the probe used in the former study. The 1C9 B cell line initially demonstrated 
an affinity for IL-2 at low factor concentrations that was fivefold lower than that 
of the human T cells (Table I). After 2 mo in culture, however, its level of 
receptors and the apparent affinity both declined. Freshly thawed cultures 
underwent the same apparent decline in affinity. The high-affinity factor binding 
sites on the murine CTLL-2 line had a dissociation constant comparable to that 
previously measured (3). In contrast, the CTL and HT-2 lines appeared to have 
threefold lower affinities for IL-2 for this range of factor concentrations (Table 
I). 
Scatchard analysis of the assay results at high IL-2 concentrations u ing PHA- 
lymphoblasts and HUT 102B2 cells (Fig. 7) demonstrated that the data formed 
curvilinear plots indicative either of a mixture of binding sites with different 
affinities or of negative cooperativity. It should be noted that the results were 
first corrected for nonspecific, nonsaturable binding before they were plotted. 
If the contribution of the high-affinity sites of each cell type was first subtracted, 
the plots usually approximated straight lines (Fig. 7B). The Ka for the various 
types of human cells was roughly 30 nM, indicating that this class of receptors 
had an affinity over 5,000 times lower than that of the high-affinity IL-2 binding 
sites. A similar dissociation constant was found for the three IL-2-dependent 
murine T cell lines (Fig. 8, Table I). The CTL and HT-2 lines expressed a much 
higher density of low-affinity binding sites on their surface than the CTLL-2 
cells. For both these lines, the high-affinity sites represented a minor fraction of 
the total binding. As a consequence, the Scatchard plots at high IL-2 concentra- 
tions were nearly linear (Fig. 8B), even without correction for the high-affinity 
binding component. 
Using [3H]anti-Tac, the number and affinity of antibody-binding sites were 
estimated for each of the human cell types. As shown in Fig. 9 for a representative 
experiment, saturable binding of the antibody occurred on both PHA-lympho- 
blasts and HUT 102B2 cells and the Scatchard analysis demonstrated a single 
class of binding sites. Preliminary results with Fab fragments of anti-Tac sug- 
gested that the binding of the intact antibody, as measured under these condi- 
tions, was monovalent (J. M. Depper and W. C. Greene, unpublished observa- 
tion). Thus, assuming only a one-to-one ratio of bound antibody to Tac protein, 
the average number of Tac proteins on the various human cell types was found 
to be reasonably close (usually within a factor of 2) to the average number of 
total IL-2 binding sites (Table I). This result suggests that each 55,000 mol wt 
Tac molecule is capable of binding one molecule of IL-2. The total number of 
factor binding sites was somewhat lower than the number of anti-Tac binding 
sites in the case of the PHA-lymphoblasts and HUT 102B2 cells. For the 
stimulated HSB2 cells and the two Tac-positive B cell samples, the number of 
IL-2 binding sites equaled or slightly exceeded (1C9 cells) the number of sites 
detected with radiolabeled antibody (Table I). 
The apparent affinity of anti-Tac binding was ~40-fold lower than that of 
high-affinity IL-2 binding to the HUT 102B2 cells but ~200-fold higher than 
that of the low-affinity IL-2 phenomenon (Table I). These values are quite similar 
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to the ratios obtained from competition binding analysis. It took a 55-fold molar 
excess of anti-Tac to reduce high-affinity IL-2 binding on HUT 102B2 cells by 
half, but only a 1:130 ratio of antibody to IL-2 to block low-affinity factor 
binding by an equal amount (Fig. 4). Similarly, in the reverse xperiment, it took 
a 100-fold molar excess of IL-2 to block the binding of [3H]anti-Tac to the 
1140 LOW AND HIGH AFFINITY IL-2 RECEPTORS 
predominant low-affinity receptors by 50%, but only a 1:60 ratio of IL-2 to 
antibody to block the binding of anti-Tac to the small fraction of high-affinity 
IL-2 binding sites (HUT 102B2 cells, Fig. 5). 
Discussion 
The original radiolabeled IL-2 binding studies of Robb et al. (3) demonstrated 
that the growth factor interacted with activated T cells with a particularly high 
affinity. This and subsequent investigations (4, 19) provided substantial evidence 
that the high-affinity interaction directly correlated with the physiological re- 
sponse of these cells to IL-2. In separate studies, the cellular site for growth 
factor binding was shown to be associated with the protein recognized by the 
anti-Tac monoclonal antibody (6-8). Nevertheless, discrepancies between the 
IL-2 and anti-Tac binding assays raised questions as to whether the factor and 
antibody-reactive sites were due to coincident, or merely overlapping, sets of 
molecules (10). For the particular cell types studied here, three lines of evidence 
argue that the sets are, in fact, coincident. First, inclusion of the low-affinity 
phenomenon i the total for IL-2 binding greatly reduced the numerical dis- 
crepancy between the IL-2 and anti-Tac binding assays (Table I). The relatively 
minor quantitative difference remaining could certainly be due to inherent errors 
in estimation of the specific radioactivity of one or both probes. The radiolabeled 
IL-2 preparation, for example, required an indirect approach for estimation of 
its protein content (see Materials and Methods). In addition, potential endoge- 
nous production of IL-2 or other growth-promoting substances (21) may have 
competed for some of the radiolabeled factor binding in the case of the PHA- 
lymphoblasts and HUT 102B2 cells. The level of low-affinity IL-2 binding may 
also have been underestimated due to overcompensation for nonspecific inter- 
action of IL-2 with the cells. Second, inclusion of unlabeled anti-Tac antibody 
substantially inhibited binding of radiolabeled IL-2 over the entire range of 
IL-2 concentrations (Fig. 4), indicating that the low-affinity, as well as the high- 
affinity, binding was probably attributable to the Tac protein. Thus, in the case 
of the HUT 102B2 cells, the low-affinity interaction, in addition to being largely 
saturable (Fig. 3), was not due to cross-reaction with an unrelated surface 
receptor. Finally, excess IL-2 totally blocked radiolabeled anti-Tac binding (Fig. 
5), implying that all Tac proteins were capable of recognizing IL-2 with some 
affinity. The detection of a large pool of low-affinity factor binding sites on the 
murine cell lines suggests that a multiplicity of binding affinities explains a similar 
quantitative discrepancy with the anti-receptor antibody studies in that species. 
The near equivalence of the binding site numbers obtained in the IL-2 and 
anti-Tac assays for PHA-lymphoblasts is consistent with the finding for this cell 
type that anti-Tac and IL-2-coupled affinity supports were each capable of 
removing all the cellular proteins reactive with the alternative support (7). 
Furthermore, the relationship between the affinities of the two types of IL-2 
binding sites and that of the anti-Tac antibody provides a potential explanation 
for the seemingly contradictory finding that a large molar excess of each ligand 
was necessary to block the binding of the other ligand (Figs. 4 and 5; references 
7 and 9). Based on the ratios of affinities, a molar excess of antibody would be 
necessary to block high-affinity IL-2 binding with its 40-fold lower dissociation 
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constant. On the other hand, a molar excess of IL-2 would be necessary to block 
binding of anti-Tac to the more prevalent low-affinity IL-2 sites, since for this 
class of receptors the antibody has the higher affinity. This simple model assumes 
that the antibody and IL-2 interact with the Tac protein at overlapping sites and 
that the inhibition of binding arises from steric hindrance. More complicated 
models would have to be invoked if the two ligands bind at distant sites on the 
Tac molecule and block each other's binding by inducing conformationa] 
changes. 
To a first approximation, the IL-2 binding appeared to be composed of a 
single high-affinity and a single low-affinity component (Fig. 7B). It was difficult, 
however, to distinguish between the existence of two distinct binding phenomena 
and a mixture of sites with a continuous range of affinities. Moreover, negative 
cooperativity between receptor molecules could account for some of the apparent 
differences in affinity and the curvature of the low-affinity Scatchard plots (22). 
The variability seen within a species in the dissociation constant for the high- 
affinity binding phenomenon (i.e., early and late IC9 cultures and the three IL- 
2-dependent murine lines) was unexpected considering the consistency seen in 
a previous urvey of receptor-positive c lls (23). Since equilibrium binding can 
be affected by such things as ligand-receptor internalization and ligand degra- 
dation, however, conclusions about the variable nature of the IL-2 binding must 
await additional approaches, including kinetic analysis of ligand binding on 
isolated cell membranes and molecular analysis of the different states of the 
receptor molecule. The apparent dissociation constants listed in Table I result 
from the use of a certain methodology and set of conditions and arise from a 
simplistic mathematical derivation (Fig. 7 B). Although these values may thus be 
biased, any errors will have a negligible ffect upon the enormous difference in 
Kd's measured for the high and low affinity classes of IL-2 receptors and thus 
will not alter the central argument that IL-2 can interact with certain cells with 
more than a single affinity. 
The Tac protein was recently purified to homogeneity by immunoaffinity 
chromatography (24). Amino-terminal sequence analysis indicated the presence 
of a single polypeptide chain. Using a synthetic oligonucleotide probe based on 
the sequence information, cDNAs corresponding to the IL-2 receptor mRNA 
were isolated and sequenced. Expression of one of these cDNA clones in Cos-1 
cells resulted in display of molecules on the cell surface that were capable of 
binding radiolabeled IL-2 and anti-Tac (24). Moreover, examination of several 
cell types using the cDNA clone suggested that a single structural gene coded 
for this component of the IL-2 receptor (24). Thus, molecular heterogeneity of 
the Tac protein (25) is probably generated by differences in posttranslational 
modifications, which include sulfation, disulfide bonding, phosphorylation, and 
extensive glycosylation. 2 Such differences could account for the disparity between 
low and high affinity IL-2 binding. Although each of the precursors in the 
maturation of the Tac protein was capable of binding to an IL-2-coupled affinity 
Leonard, W. J., J. M. Depper, M. Kr6nke, R.J. Robb, T. A. Waldmann, and W. C. Greene. The 
human receptor for T-cell growth factor (TCGF): evidence for sulfation, phosphorylation, variable 
post-translational processing, and the ability of precursor forms of the receptor to bind TCGF. 
Submitted for publication. 
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support, 2it was not possible from that analysis to determine whether their affinity 
for IL-2 varied. 
The finding of IL-2 binding sites with multiple affinities is not unexpected, 
given the results obtained with other polypeptide growth factors. The receptor 
for nerve growth factor was shown to exist in two states which differed in affinity 
17-fold (26, 27). These forms could be interconverted by interaction with wheat 
germ agglutinin, indicating that the affinity differences were due to conforma- 
tional changes (26, 28). Similarly, the receptor for epidermal growth factor was 
found to exist in low and high affinity states (29), which could be interconverted 
by binding of a monoclonal anti-receptor antibody (30). As with IL-2 and T cell 
proliferation, the less numerous high-affinity sites appeared to be responsible for 
the growth-promoting properties of epidermal growth factor on one particular 
cell line (29). Finally, cellular receptors for platelet-derived growth factor were 
also shown to express two distinctly different affinities, depending upon condi- 
tions of temperature and ligand binding (31). Thus, in addition to potential 
differences in posttranslational modification, the variation in IL-2 receptor 
affinity could be due to conformational changes caused by interaction of the Tac 
protein with a different hypothetical receptor subunit (10) or by dimerization of 
the Tac molecule, as was postulated in the case of the nerve growth factor 
receptor (28). Alternatively, separate high and low affinity binding sites for IL- 
2 could be present on the same molecule. 
The low-affinity IL-2 binding sites were found on all Tac-positive cells tested 
but not on several Tac-negative lines (Table I). The presence of both high and 
low affinity IL-2 receptors on the 1C9 B cell line and the B cells obtained from 
the HCi sample was unusual but not without precedence (32). Selected EBV- 
transformed B cell lines, mitogen-activated normal B cells, and B cells from 
patients with hairy cell leukemia (HCL) were all shown to display the Tac protein 
(32, 33). In fact, one such B cell line was shown to respond to low concentrations 
of homogeneous IL-2 with increased immunoglobulin secretion (32). As ex- 
pected, this response was blocked by the anti-Tac antibody. The excess of IL-2 
binding sites over antibody binding sites on the 1 C9 cell line, however, raises the 
possibility that a fraction of the low-affinity sites on this particular line might 
represent cross-reaction with a surface component which is unrelated to the Tac 
protein. 
The proportion of high and low affinity binding sites for the different cell 
types varied (Table I). For example, most of the initial increase in Tac expression 
upon restimulation of 9-d-old PHA-lymphoblasts corresponded to low-affinity 
sites. The same was found for PMA-induced receptors on HSB2 cells and the 
receptors displayed on the B cells in the HCL sample. In addition, the ratio of 
low to high affinity binding for the murine CTL and HT-2 lines was higher than 
that for the CTLL-2 line. Thus, display of the protein recognized by the anti- 
Tac or 7D4 antibodies was not always a quantitative measure of the capacity of 
the cells for high affinity interaction with IL-2. Analysis of IL-2 receptor 
expression should therefore include a determination of the relative prevalence 
of high and low affinity IL-2 binding sites. 
The low-affinity binding sites for IL-2 are unlikely to directly participate in 
normal physiological responses to the factor, since at concentrations that might 
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occur in vivo (<200 pM) 3 only a minute fraction (<1%) of such sites would be 
occupied. In contrast, the same concentration would saturate the high-affinity 
sites. Nevertheless, a high enough local concentration f IL-2 might momentarily 
exist if the producing and responding cells are in contact or if the secreting cell 
also displays low-affinity receptors. Moreover, the low-affinity sites may act as a 
pool of components for generation of high-affinity receptors. If ways can be 
found to interconvert high and low affinity IL-2 binding sites, as was done for 
the nerve growth factor receptor (26), it may be possible to conclusively deter- 
mine the contribution of each form of the molecule to any particular physiological 
response. In the meantime, there is ample reason to exercise caution in inter- 
preting the results of experiments employing high concentrations of IL-2. In 
each case, the factor concentration necessary for the cellular esponse should be 
compared with the dissociation constant(s) and density of the IL-2 receptors. 
Both of the latter factors will be crucial in determining the extent of the response 
(4). If the analysis indicates that few, if any, receptors are present with an 
appropriate affinity, then alternative xplanations, uch as contaminants in the 
IL-2 preparation, should be explored. Similarly, putative responses to IL-2 by 
cells that are negative for the Tac protein may represent the effects of contami- 
nants in the IL-2 preparation or an indirect effect upon residual T cells in the 
cell population (34). In addition, they might be due to cross-reaction of IL-2 at 
very high concentrations with receptors for distinct growth or differentiation 
factors. In fact, the latter possibility has been invoked to explain the IL-2- 
dependent induction of immunoglobulin secretion for a Tac-negative B cell line, 
SKW6.4 (35). Clearly, attribution of physiological effects to the kind of low- 
affinity IL-2 receptor described here requires the elimination of several compet- 
ing explanations. 
Summary 
Interleukin 2 promotes proliferation of T cells by virtue of its interaction with 
a high-affinity cell surface receptor. This receptor isa 55,000 mol wt glycoprotein 
that is also recognized by the murine monoclonal ntibody, anti-Tac. Quantitative 
binding studies with radiolabeled IL-2 and anti-Tac, however, initially indicated 
far more antibody binding sites per cell than IL-2 binding sites. Extension of the 
IL-2 binding analysis to concentrations several thousand-fold higher than that 
necessary for the T cell proliferative response demonstrated the existence of a 
class (or classes) of low-affinity IL-2 binding sites. Inclusion of the low-affinity 
IL-2 binding greatly reduced the quantitative discrepancy in the ligand binding 
assays. That the low-affinity binding, as well as the high-affinity interaction, was 
associated with the Tac molecule was indicated by the finding that the antibody 
could substantially or totally block the entire spectrum of IL-2 binding and by 
the finding that IL-2 could in turn block all radiolabeled anti-Tac binding. The 
low-affinity sites were found on activated T cells, several human and murine T 
cell lines and two examples of Tac-positive B cells. The physiological role of the 
low-affinity IL-2 binding sites and the molecular changes in the Tac protein that 
give rise to the affinity differences remain open to investigation. 
3 Equivalent to the typical concentration of IL-2 released in vitro after 24 h by 1 x 106 PBL/m] 
following stimulation with PHA or by a mixed lymphocyte reaction. 
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